The role of NOP58 in prostate cancer progression through SUMOylation regulation and drug response
NOP58 is a key regulator of prostate cancer progression through its mediation of the SUMOylation pathway. Its expression level serves as a reliable prognostic biomarker and an actionable therapeutic target, advancing precision medicine for prostate cancer. Targeting NOP58 may enhance therapeutic efficacy and improve outcomes in oncology.
Authors
- Tao Liu (ORCID: https://orcid.org/0000-0001-9005-8414)
- Kaichen Wang (ORCID: https://orcid.org/0000-0002-0845-5291)
- Shi Zong (ORCID: https://orcid.org/0000-0001-9720-6336)
- Wei Guo (ORCID: https://orcid.org/0000-0002-8124-5186)
- Chao Yi
Institutions
- First Bethune Hospital of Jilin University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-10-18
- DOI
- https://doi.org/10.3389/fphar.2024.1476025
- Citations
- 7
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.93